
About Prism Medico
Prism Medico is a publicly listed company based in Bengaluru (India) founded in 1985. Drugs for multiple therapeutic areas are manufactured through RD efforts. Its Indian entity Prism Medico And Pharmacy Limited reported revenue of ₹2.47 Cr. Its focus areas include Diversified Pharmaceuticals and Drugs.
Company details
Prism Medico was established in 1985 and is headquartered in Bengaluru, India. Operations center on research and development within the pharmaceutical sector, where drugs are produced for diverse therapeutic areas. Manufacturing processes are managed to support various medical needs, with activities conducted primarily from the Indian base. The companys domain, prismmedico.in, facilitates online presence for industry engagement.
- Headquarters Bengaluru, India
- Stage Public
- SectorsHealthcare
- Website prismmedico.in
- Legal Name Prism Medico & Pharmacy Ltd.
- Market Cap₹47.44 Cr
PRISMMEDI · BSE
- Share Price₹35.00
+0.06% today
- Revenue₹54.43 Cr
FY 2018-19 · +138.7% YoY
- EBITDA₹0.12 Cr
Margin 0.2%
- Net Profit₹0.16 Cr
FY 2018-19 · +633.3% YoY
- ROE1.1%
ROCE 1.6%
- Debt / Equity0.17
Interest cover -42.3x
Associated legal entities of Prism Medico
Prism Medico operates through Prism Medico And Pharmacy Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Prism Medico And Pharmacy Limited Listed CIN L24100HP2002PLC009299 | Active | 22 Mar 2002 | Kala Amb, Himachal Pradesh | ₹2.5 Cr | 6 | View details |
Board of directors of Prism Medico And Pharmacy Limited (Prism Medico)
Prism Medico And Pharmacy Limited is the primary company behind Prism Medico. The board of Prism Medico And Pharmacy Limited currently have 4 directors; the longest-serving is Davender Singh, appointed in 2022. 14 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Davender Singh DIN 09447213 | Director | 31 Jan 2022 | 4 yrs 9 mo | Prism Medico And Pharmacy Limited |
| Pardeep Kumar DIN 09451568 | Director | 31 Jan 2022 | 4 yrs 9 mo | Prism Medico And Pharmacy Limited |
| Sakshi Laller DIN 10163397 | Whole-time director | 16 May 2023 | 3 yrs 6 mo | Prism Medico And Pharmacy Limited |
| Dinesh Kumar DIN 01149388 | Director | 14 Aug 2023 | 3 yrs 3 mo | Prism Medico And Pharmacy Limited |
IPO & Listings of Prism Medico
Prism Medico is a publicly listed company on the BSE with ticker symbol PRISMMEDI in India, operating in the Finance sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date23 Oct 1985
- Listed onBSE: 512217
- Listed entityPrism Medico & Pharmacy Ltd.
- Exchange sectorFinance
- ISININE730E01016
- Share price₹31.99 (+1.39% on the day) · 2026-10-14
- Market capitalisation₹42.8 Cr
- Price to earnings17.6
- EPS (diluted, trailing year)₹-0.60
- Volume (last session)22,014
Financials of Prism Medico
Exchange-reported figures of Prism Medico And Pharmacy Limited, the listed company behind Prism Medico (BSE: PRISMMEDI).
Financial Highlights
FY 2018-19 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2018-19 | FY 2017-18 | FY 2016-17 |
|---|---|---|---|
| Income statement | |||
| Revenue | 54.43 | 22.80 | 5.27 |
| Revenue growth | +138.7% | +332.6% | - |
| EBITDA | 0.12 | 0.76 | 0.07 |
| EBITDA margin | +0.2% | +3.3% | +1.3% |
| Profit before tax | (0.07) | 0.06 | (0.21) |
| Net profit | 0.16 | (0.03) | (0.22) |
| Net profit margin | +0.3% | -0.1% | -4.2% |
| EPS (₹) | 0.07 | 0.00 | 0.00 |
| Balance sheet | |||
| Total assets | 15.21 | 15.07 | 16.38 |
| Net worth | 12.91 | 12.87 | 12.87 |
| Total debt | 2.27 | 2.18 | 3.50 |
| Cash & bank | 0.41 | 1.36 | 1.95 |
| Net working capital | 4.85 | 3.18 | 6.42 |
| Cash flow | |||
| Cash from operations | (0.44) | 3.55 | 0.00 |
| Cash from investing | 0.00 | (2.53) | 0.00 |
| Cash from financing | (0.50) | (1.61) | 0.00 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 2.44 | 0.63 | 2.93 | 1.27 | 8.44 | 16.76 | 26.89 |
| Revenue growth | +287.3% | -78.5% | +130.7% | -85.0% | -49.6% | -37.7% | - |
| EBITDA | 0.41 | (0.08) | (0.13) | (0.10) | (0.50) | (0.17) | (0.05) |
| EBITDA margin | +16.8% | -12.7% | -4.4% | -7.9% | -5.9% | -1.0% | -0.2% |
| Profit before tax | 0.44 | (0.06) | (0.03) | (0.11) | (0.51) | (0.18) | (0.07) |
| Net profit | 0.33 | (0.04) | (0.02) | (0.08) | (0.38) | (0.13) | (0.05) |
| Net profit margin | +13.5% | -6.4% | -0.7% | -6.3% | -4.5% | -0.8% | -0.2% |
| EPS (₹) | 0.53 | (0.08) | (0.04) | (0.13) | (0.61) | (0.21) | (0.08) |
| Balance sheet | |||||||
| Total assets | 15.41 | 15.09 | 15.14 | 15.16 | 12.55 | 12.93 | 13.06 |
| Net worth | 15.41 | 15.09 | 15.14 | 15.16 | 12.55 | 12.92 | 13.05 |
| Total debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash & bank | 0.06 | 0.07 | 0.08 | 0.10 | 0.06 | 0.08 | 0.11 |
| Net working capital | 15.25 | 14.83 | 14.89 | 14.92 | 12.32 | 10.86 | 11.04 |
| Cash flow | |||||||
| Cash from operations | 0.00 | (0.02) | (0.01) | 2.95 | (2.38) | (0.05) | (4.36) |
| Cash from investing | 0.00 | 0.00 | 0.00 | (2.91) | 2.35 | 0.02 | 4.36 |
| Cash from financing | 0.00 | 0.00 | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.18 | 0.00 | 0.28 | 0.07 | 0.50 | 1.59 | 0.07 | 0.21 |
| Revenue growth (YoY) | -64.0% | -100.0% | +300.0% | -66.7% | +72.4% | +2550.0% | - | - |
| Other income | 0.26 | 0.09 | 0.00 | 0.01 | 0.02 | 0.00 | 0.01 | 0.00 |
| Total expenses | 0.22 | 0.15 | 0.41 | 0.09 | 0.60 | 0.94 | 0.06 | 0.22 |
| EBITDA | (0.04) | (0.15) | (0.13) | (0.02) | (0.10) | 0.65 | 0.01 | (0.01) |
| EBITDA margin | -22.2% | - | -46.4% | -28.6% | -20.0% | +40.9% | +14.3% | -4.8% |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.22 | (0.06) | (0.13) | (0.01) | (0.08) | 0.65 | 0.02 | (0.01) |
| Tax | 0.00 | 0.00 | 0.12 | 0.00 | 0.00 | (0.01) | (0.02) | 0.00 |
Financial Statements
| Particulars | FY 2018-19 | FY 2017-18 | FY 2016-17 |
|---|---|---|---|
| Revenue | 54.43 | 22.80 | 5.27 |
| Revenue growth | +138.7% | +332.6% | - |
| Other income | 0.30 | 0.04 | 0.07 |
| Total expenses | 54.31 | 22.04 | 5.20 |
| Employee cost | 0.27 | 0.21 | 0.28 |
| EBITDA | 0.12 | 0.76 | 0.07 |
| EBITDA margin | +0.2% | +3.3% | +1.3% |
| Depreciation | 0.38 | 0.45 | 0.21 |
| Interest | 0.11 | 0.29 | 0.14 |
| Profit before tax | (0.07) | 0.06 | (0.21) |
| Tax | (0.13) | 0.07 | 0.01 |
| Net profit | 0.16 | (0.03) | (0.22) |
| Net profit margin | +0.3% | -0.1% | -4.2% |
| EPS (₹) | 0.07 | 0.00 | 0.00 |
| Particulars | FY 2018-19 | FY 2017-18 | FY 2016-17 |
|---|---|---|---|
| Equity & liabilities | |||
| Share capital | 6.06 | 6.06 | 6.06 |
| Reserves & surplus | 6.85 | 6.81 | 6.81 |
| Shareholders' funds (net worth) | 12.91 | 12.87 | 12.87 |
| Minority interest | 0.00 | 0.00 | 0.00 |
| Secured loans | 2.27 | 1.25 | 0.27 |
| Unsecured loans | 0.00 | 0.93 | 3.23 |
| Total debt | 2.27 | 2.18 | 3.50 |
| Total liabilities | 15.21 | 15.07 | 16.38 |
| Assets | |||
| Gross block | 10.22 | 10.23 | 10.44 |
| Net block | 8.91 | 9.31 | 9.91 |
| Capital work in progress | 0.00 | 0.00 | 0.00 |
| Investments | 1.36 | 2.61 | 0.00 |
| Inventories | 1.39 | 1.49 | 3.41 |
| Sundry debtors | 3.13 | 0.00 | 0.71 |
| Cash & bank balances | 0.41 | 1.36 | 1.95 |
| Loans & advances | 5.92 | 0.98 | 1.23 |
| Total current assets | 10.85 | 3.83 | 7.30 |
| Total current liabilities | 6.00 | 0.65 | 0.88 |
| Net working capital | 4.85 | 3.18 | 6.42 |
| Total assets | 15.21 | 15.07 | 16.38 |
| Particulars | FY 2018-19 | FY 2017-18 | FY 2016-17 |
|---|---|---|---|
| Opening cash | 1.35 | 1.95 | 0.00 |
| Net cash from operating activities | (0.44) | 3.55 | 0.00 |
| Net cash from investing activities | 0.00 | (2.53) | 0.00 |
| Net cash from financing activities | (0.50) | (1.61) | 0.00 |
| Net change in cash | (0.95) | (0.59) | 0.00 |
| Closing cash | 0.41 | 1.36 | 1.95 |
| Particulars | FY 2018-19 | FY 2017-18 | FY 2016-17 |
|---|---|---|---|
| Growth | |||
| Sales growth | +138.7% | +332.6% | - |
| EBITDA growth | -84.2% | +985.7% | - |
| PBT growth | - | +9998.0% | +9997.0% |
| Net income growth | +633.3% | +86.4% | - |
| Profitability & leverage | |||
| Net income margin | +0.1% | -0.0% | -4.2% |
| Return on capital employed | +1.6% | +2.8% | -0.4% |
| Return on net worth | +1.1% | -0.2% | -1.7% |
| Debt / equity | 0.17 | 0.22 | 0.27 |
| Long-term debt / equity | 0.00 | 0.12 | 0.23 |
| Interest cover | -42.31 | 93.55 | -100.00 |
| Efficiency & per share | |||
| Fixed asset turnover | 5.32 | 2.21 | 0.53 |
| Inventory turnover | 37.80 | 9.31 | 1.64 |
| Debtors turnover | 34.78 | 64.23 | 7.86 |
| EPS (₹) | 0.07 | 0.00 | 0.00 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 21.29 | 21.23 | 21.24 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.18 | 0.00 | 0.28 | 0.07 | 0.50 | 1.59 | 0.07 | 0.21 |
| Revenue growth (YoY) | -64.0% | -100.0% | +300.0% | -66.7% | +72.4% | +2550.0% | - | - |
| Other income | 0.26 | 0.09 | 0.00 | 0.01 | 0.02 | 0.00 | 0.01 | 0.00 |
| Total expenses | 0.22 | 0.15 | 0.41 | 0.09 | 0.60 | 0.94 | 0.06 | 0.22 |
| EBITDA | (0.04) | (0.15) | (0.13) | (0.02) | (0.10) | 0.65 | 0.01 | (0.01) |
| EBITDA margin | -22.2% | - | -46.4% | -28.6% | -20.0% | +40.9% | +14.3% | -4.8% |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.22 | (0.06) | (0.13) | (0.01) | (0.08) | 0.65 | 0.02 | (0.01) |
| Tax | 0.00 | 0.00 | 0.12 | 0.00 | 0.00 | (0.01) | (0.02) | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 2.44 | 0.63 | 2.93 | 1.27 | 8.44 | 16.76 | 26.89 |
| Revenue growth | +287.3% | -78.5% | +130.7% | -85.0% | -49.6% | -37.7% | - |
| Other income | 0.03 | 0.02 | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total expenses | 2.03 | 0.71 | 3.06 | 1.37 | 8.94 | 16.93 | 26.94 |
| Employee cost | 0.06 | 0.04 | 0.03 | 0.05 | 0.19 | 0.17 | 0.22 |
| EBITDA | 0.41 | (0.08) | (0.13) | (0.10) | (0.50) | (0.17) | (0.05) |
| EBITDA margin | +16.8% | -12.7% | -4.4% | -7.9% | -5.9% | -1.0% | -0.2% |
| Depreciation | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 |
| Interest | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.44 | (0.06) | (0.03) | (0.11) | (0.51) | (0.18) | (0.07) |
| Tax | 0.11 | (0.02) | (0.01) | (0.03) | (0.13) | (0.05) | (0.02) |
| Net profit | 0.33 | (0.04) | (0.02) | (0.08) | (0.38) | (0.13) | (0.05) |
| Net profit margin | +13.5% | -6.4% | -0.7% | -6.3% | -4.5% | -0.8% | -0.2% |
| EPS (₹) | 0.53 | (0.08) | (0.04) | (0.13) | (0.61) | (0.21) | (0.08) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 6.06 | 6.06 | 6.06 | 6.06 | 6.06 | 6.06 | 6.06 |
| Reserves & surplus | 9.35 | 9.03 | 9.08 | 9.10 | 6.49 | 6.86 | 6.99 |
| Shareholders' funds (net worth) | 15.41 | 15.09 | 15.14 | 15.16 | 12.55 | 12.92 | 13.05 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total liabilities | 15.41 | 15.09 | 15.14 | 15.16 | 12.55 | 12.93 | 13.06 |
| Assets | |||||||
| Gross block | 0.03 | 0.03 | 0.03 | 0.03 | 0.05 | 0.22 | 0.22 |
| Net block | 0.03 | 0.03 | 0.03 | 0.03 | 0.05 | 0.06 | 0.07 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.94 | 1.94 |
| Inventories | 6.77 | 6.77 | 6.77 | 6.77 | 6.77 | 4.85 | 0.05 |
| Sundry debtors | 3.93 | 3.58 | 3.69 | 4.76 | 4.88 | 13.51 | 18.34 |
| Cash & bank balances | 0.06 | 0.07 | 0.08 | 0.10 | 0.06 | 0.08 | 0.11 |
| Loans & advances | 4.69 | 4.88 | 4.45 | 3.52 | 0.63 | 1.04 | 1.07 |
| Total current assets | 15.45 | 15.30 | 14.99 | 15.15 | 12.34 | 19.48 | 19.57 |
| Total current liabilities | 0.20 | 0.47 | 0.10 | 0.23 | 0.02 | 8.62 | 8.53 |
| Net working capital | 15.25 | 14.83 | 14.89 | 14.92 | 12.32 | 10.86 | 11.04 |
| Total assets | 15.41 | 15.09 | 15.14 | 15.16 | 12.55 | 12.93 | 13.06 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.07 | 0.08 | 0.10 | 0.06 | 0.08 | 0.11 | 0.12 |
| Net cash from operating activities | 0.00 | (0.02) | (0.01) | 2.95 | (2.38) | (0.05) | (4.36) |
| Net cash from investing activities | 0.00 | 0.00 | 0.00 | (2.91) | 2.35 | 0.02 | 4.36 |
| Net cash from financing activities | 0.00 | 0.00 | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 |
| Net change in cash | 0.00 | (0.02) | (0.01) | 0.04 | (0.03) | (0.03) | (0.01) |
| Closing cash | 0.06 | 0.07 | 0.08 | 0.10 | 0.06 | 0.08 | 0.11 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +287.3% | -78.5% | +130.7% | -85.0% | -49.6% | -37.7% | - |
| EBITDA growth | +612.5% | +38.5% | -30.0% | +80.0% | -194.1% | -240.0% | - |
| PBT growth | +9998.0% | -100.0% | +72.7% | +78.4% | -183.3% | -157.1% | - |
| Net income growth | +925.0% | -100.0% | +75.0% | +79.0% | -192.3% | -160.0% | - |
| Revenue CAGR (3Y) | +24.3% | -57.9% | -44.1% | -63.9% | -38.5% | -7.2% | +568.5% |
| EBITDA CAGR (3Y) | - | -45.7% | -8.6% | +26.0% | - | - | -43.7% |
| Profitability & leverage | |||||||
| Net income margin | +13.5% | -6.4% | -0.7% | -6.3% | -4.5% | -0.8% | -0.2% |
| Return on capital employed | +2.8% | -0.5% | -0.1% | -0.8% | -3.9% | -1.4% | -0.5% |
| Return on net worth | +2.1% | -0.3% | -0.1% | -0.6% | -2.9% | -1.0% | -0.4% |
| Debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 0.00 | 0.00 | -7.14 | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 81.33 | 21.00 | 97.67 | 31.75 | 62.52 | 76.18 | 122.23 |
| Inventory turnover | 0.36 | 0.09 | 0.43 | 0.19 | 1.45 | 6.84 | 53.25 |
| Debtors turnover | 0.65 | 0.17 | 0.69 | 0.26 | 0.92 | 1.05 | 2.43 |
| EPS (₹) | 0.53 | (0.08) | (0.04) | (0.13) | (0.61) | (0.21) | (0.08) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 25.42 | 24.89 | 24.97 | 25.01 | 20.71 | 21.32 | 21.53 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Prism Medico
Complete news archive for Prism Medico
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Prism Medico
Prism Medico was founded in 1985.
Prism Medico is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
The primary company behind Prism Medico, Prism Medico And Pharmacy Limited, reported revenue of ₹2.47 Cr for FY 2026, up 287% year on year.
Prism Medico was established in 1985 and is headquartered in Bengaluru, India. Operations center on research and development within the pharmaceutical sector, where drugs are produced for diverse therapeutic areas. Manufacturing processes are managed to support various medical needs, with activities conducted primarily from the Indian base. The companys domain, prismmedico.in, facilitates online presence for industry engagement.
Yes, Prism Medico is publicly traded on BSE under the ticker symbol PRISMMEDI.
Prism Medico operates through Prism Medico And Pharmacy Limited.
The legal entities of Prism Medico currently have 6 directors, including Davender Singh, Pardeep Kumar, Sameer Gupta and others.
